← Back to headlines
AbbVie's Skyrizi and Rinvoq Drive Growth Amid Humira Decline
AbbVie's growth is being fueled by the strong performance of its drugs Skyrizi and Rinvoq, even as sales of its long-standing blockbuster Humira continue to decline.
31 Jul, 12:08 — 31 Jul, 12:08
Sources
Showing 1 of 1 sources
Related Stories
Nvidia Nears $14 Billion Acquisition Deal for AI Startup Hugging Face
22m ago
US-Iran Strikes Trigger Oil Surge and Global Market Volatility
36m ago
Bessent Defends Economic Pressure Strategy Against Iran and Tariff Proposals
52m ago
Casablanca Airport Sets Daily Passenger Record Amid Summer Travel Surge
1h ago